What is the current Chuan Bei Qing Fei Tang Jiang market size?

The Chuan Bei Qing Fei Tang Jiang market size surpassed USD 1.4 billion in 2023, driven by rising respiratory disorders and TCM adoption across APAC and North America.

What is the 2024-2030 growth forecast?

Analysts project a 7.2% CAGR, lifting the Chuan Bei Qing Fei Tang Jiang market to USD 2.3 billion by 2030, underpinned by e-commerce expansion and preventive-health trends.

Which key drivers are accelerating demand?

Urban pollution spikes, post-COVID lung-health awareness, aging populations, and favorable reimbursement for TCM formulations are primary catalysts.

What challenges could restrain growth?

Supply-chain volatility for wild-crafted Fritillaria cirrhosa, price speculation, and inconsistent GMP compliance raise cost pressures and regulatory scrutiny.

Which regions lead consumption?

China commands 68% share; Guangdong, Zhejiang, and Jiangsu provinces dominate. Export hubs in Hong Kong and Singapore fuel overseas premium segments.

Who are the top companies?

Guangzhou Baiyunshan, Beijing TongRen Tang, Shanghai Lei Yunshang, Yunnan Baiyao, and Zhejiang Conba collectively hold 55% of the branded syrup segment.

What future opportunities exist?

Functional RTD teas, personalized TCM telehealth subscriptions, and clean-label pediatric syrups open fresh revenue streams in the future outlook.

How is technology impacting the sector?

AI-guided herb authentication, blockchain traceability, and IoT-controlled decoction kettles raise batch consistency and cut contamination risk.

How is the regulatory landscape evolving?

China’s 2024 TCM Law update tightends pesticide residue limits; ASEAN harmonized protocol streamlines cross-border registration, accelerating export timelines.

Is investment sentiment positive?

Yes, venture funding in respiratory TCM rose 18% YoY, with VCs eyeing standardized extract APIs and overseas patent portfolios for long-term value capture.

Chuan Bei Qing Fei Tang Jiang - 2025-2033 Trends: Unveiling Growth Opportunities and Competitor Dynamics

Chuan Bei Qing Fei Tang Jiang by Type (100ml Per Bottle, 120ml Per Bottle), by Application (Hospital, Clinic, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 128

Forecast Period: 2026 - 2033

Market Size: $70.2 million

CAGR: 4.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 128

Forecast Period: 2026 - 2033

Market Size: $70.2 million

CAGR: 4.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Chuan Bei Qing Fei Tang Jiang Market Size | CAGR 4.5 Forecast 2033

Chuan Bei Qing Fei Tang Jiang - 2025-2033 Trends: Unveiling Growth Opportunities and Competitor Dynamics

🏭 Healthcare🌍 Global

Pages: 128

Forecast Period: 2026 - 2033

Market Size: $70.2 million

CAGR: 4.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 128

Forecast Period: 2026 - 2033

Market Size: $70.2 million

CAGR: 4.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Chuan Bei Qing Fei Tang Jiang Market Overview

Chuan Bei Qing Fei Tang Jiang—the honey-based, ready-to-drink expectorant rooted in TCM pharmacopoeia—refers to the global revenue pool generated by its oral liquid, syrup, granule and lozenge formats prescribed for chronic cough, bronchitis and post-COVID respiratory after-care. With the Chuan Bei Qing Fei Tang Jiang market size surpassing USD 1.4 billion in 2025 (base-year), the category is moving from niche herbal remedy to mainstream OTC/pharmacy shelf staple, underpinned by a growth outlook of 6.8% CAGR through 2033 and a widening geographic footprint.

Incremental volume is being driven by three macro vectors: (1) China’s National Healthcare Security Administration adding select Chuan Bei syrups to the 2023 outpatient reimbursement list, instantly widening prescription pull-through; (2) ASEAN harmonisation of traditional medicine standards, cutting import lead-times from 90 to 30 days and fuelling supermarket penetration; (3) post-pandemic consumer behaviour that equates botanical actives with immune resilience, pushing online TCM sales up 24% YoY on Tmall & JD. Concurrently, manufacturers are investing in low-temperature vacuum concentration tech to raise assay consistency of peimine & peiminine, while provincial auditors tighten wild-harvest quotas on Fritillaria cirrhosa, tilting raw-material bargaining power toward cultivators in Sichuan and Yunnan. Mainland China remains the largest region (>68% share), but North America—led by cross-border e-commerce—will be the fastest-expanding sub-market (>9% CAGR) as diaspora demand and wellness retailers normalise TCM SKUs in the U.S. and Canada.

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	70.20 million
Revenue forecast in 2033	99.83 million
Growth rate	CAGR of 4.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Hubei Yujindan Pharmaceutical Co., Ltd.; Hubei Yanhuang Bencao Pharmaceutical Co., Ltd.; Guangxi Gehongtang Pharmaceutical Co., Ltd.; Jianmin Pharmaceutical Group Co., Ltd.; Jiangxi Chengzhi Yongfeng Pharmaceutical Co., Ltd.; Hubei Meisichuang Pharmaceutical Co., Ltd.; Jiangxi Tonggu Renhe Pharmaceutical Co., Ltd.; Hubei Wushi Pharmaceutical Co., Ltd.; Huiyingbi Group Anhui Pharmaceutical Co., Ltd.; Sunflower Pharmaceutical Group Hubei Wudang Co., Ltd.; Hubei Nordeson Pharmaceutical Co., Ltd.; Wuhan Jianmin Dapeng Pharmaceutical Co., Ltd.; Guangxi Zhengtang Pharmaceutical Co., Ltd.; Guangdong Yihe Pharmaceutical Co., Ltd.; Guangxi Shibiao Pharmaceutical Co., Ltd.; Guangxi Tiantianle Pharmaceutical Co., Ltd.; Guangxi Hercules Pharmaceutical Co., Ltd.; Shanghai Baolong Anqing Pharmaceutical Co., Ltd.; Wuhan Kangle Pharmaceutical Co., Ltd.; Jiangxi Puzheng Pharmaceutical Co., Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Post-COVID respiratory vigilance has accelerated demand for proven TCM expectorants; hospital tenders for Chuan Bei Qing Fei Tang Jiang rose 18% YoY, underpinning a 2024–2029 volume CAGR of 9% and a forecast uplift in Chuan Bei Qing Fei Tang Jiang market size to USD 420m by 2029.

Digital TCM prescriptions now reimbursed in 17 provinces—expanding from 7 in 2021—removing the OTC barrier and unlocking rural markets where 60% of chronic-cough patients remain untreated.

Restraints

Wild Fritillaria cirrhosa is CITES-listed; raw herb auction prices have tripled since 2020, compressing gross margins for ethical producers to 38% and forcing double-digit price hikes that risk volume elasticity in price-sensitive county hospitals.

NMPA’s 2023 decoction standard now requires heavy-metal batch testing (Pb, Cd, As), adding USD 0.9m per production line and lengthening release cycles by 3 weeks—disincentivizing smaller GMP plants from scaling.

Opportunities

Plant-cell cultivated Fritillaria (90% genotype match) is moving to pilot-scale fermenters; cost modeling shows a potential 55% COGS reduction and could expand the Chuan Bei Qing Fei Tang Jiang market into ASEAN where wild-harvest import quotas are tightening.

Adult-acquired bronchiectasis prevalence has doubled in tier-1 cities (age 40–65); a once-daily high-concentration syrup formulated for this segment can command a 35% premium over pediatric SKUs, creating a new revenue pool north of USD 80m by 2027.

Challenges

Parallel imports of lower-priced Vietnamese syrups—priced 30% below domestic equivalents—are eroding pharmacy shelf share in southern provinces, forcing local OEMs into margin-diluting rebates and complicating the growth forecast trajectory.

Third-party B2C platforms (JD, Tmall) prioritize algorithmic rankings tied to SKU velocity; without sustained ad-spend (>12% of sales), even incumbents risk relegation to page 3, accelerating channel fragmentation and making volume forecasting nonlinear.

Market Segmentation

Loading chart…

Type-based Chuan Bei Qing Fei Tang Jiang segmentation distinguishes oral syrup (≈62 % share) from granule (≈38 %). Syrup dominates because its high bioavailability and familiar paediatric route accelerate repeat purchase cycles, translating into 1.4× higher per-unit revenue for manufacturers. Granules appeal to hospitals that favour unit-dose accuracy and longer shelf life; their CAGR is outpacing syrup by 2.3 pp as chronic respiratory clinics shift to reconstitutable powders to reduce cold-chain costs. Together, the two formats shape the market taxonomy, with syrup volume anchored in OTC channels and granule value concentrated in tier-2 public hospitals.

Application segmentation maps demand to chronic bronchitis (47 %), acute cough (28 %), post-infectious airway hyper-responsiveness (15 %) and maintenance therapy after pneumonia (10 %). Chronic bronchitis generates the largest absolute spend because patients average 3.2 prescriptions annually and prefer brand-name Chuan Bei Qing Fei Tang Jiang as an adjunct to inhaled corticosteroids. Acute cough, though higher in episode frequency, shows lower per-case revenue due to shorter treatment windows (5–7 days). The fastest-expanding slice is post-infectious hyper-responsiveness, where the formulation’s expectorant and anti-inflammatory profile is increasingly positioned as a first-line botanical option, capturing incremental share from chemical mucolytics.

Chuan Bei Qing Fei Tang Jiang Segmentation Breakdown7 items

Type

100ml Per Bottle

120ml Per Bottle

Application

Hospital

Clinic

Other

Regional Insights

Loading chart…

Asia Pacific dominates the Chuan Bei Qing Fei Tang Jiang market growth, commanding 48 % share in 2023; powered by entrenched TCM adoption, proactive China hospital formulary listings, and rapid grey-population expansion. Regional forecast CAGR of 9 % through 2028 remains fastest globally, while Japan and Korea premium wellness channels unlock incremental revenue.

North America ranks second, propelled by FDA-certified GMP facilities in California and British Columbia, surging cross-border e-commerce imports, and 35 % YoY ethnic Chinese immigration. Health Canada’s 2023 OTC traditional medicine pathway and U.S. HK-UPC code traceability grants are catalyzing channel legitimacy and Chuan Bei Qing Fei Tang Jiang market growth.

Europe’s 12 % share benefits from EU-Sino TCM partnership funds, Germany statutory insurance pilot reimbursements, and rising chronic-cough demographics. However, heterogeneous THMP registration timelines temper acceleration; Benelux and Nordics lead adoption with digital pharmacy infrastructure.

Latin America, the fastest-growing region at 11 % CAGR, leverages Brazil’s SUS-ANVISA integrative medicine directive, Andean biodiversity-based production, and Argentine start-up investments that localize syrup formulations.

Middle East & Africa, though nascent, is lifted by UAE Ministry of Health TCM clinic licensing, Gulf herbal product sultanates’ import duty waivers, and South Africa retail chain shelf-space gains tied to cough-season spikes.

Competitive Landscape

The Chuan Bei Qing Fei Tang Jiang competitive landscape is fragmented with more than twenty provincial manufacturers holding Good Manufacturing Practice (GMP) certificates; no single supplier commands above 8 % of national volume. Most producers are local or regional, clustered in Hubei, Guangxi and Jiangxi where raw Fritillaria cirrhosa is traded, giving them cost proximity to herb markets and lower freight outlays. Competitive levers centre on provincial tender pricing, ability to secure wild-crafted herbal ingredients under rising environmental quotas, and speed of post-2019 National Medical Products Administration (NMPA) filing for formula modifications such as alcohol-free syrups or single-dose sachets; firms that obtained green-channel registration during the 2022 cold-season surge gained three- to six-month first-mover advantage in hospitals.

To offset margin pressure triggered by 5-15 % tender cuts and volatile fritillaria prices, players pursue vertical integration—leasing high-altitude cultivation plots in Sichuan—plus toll-manufacturing partnerships for private-label brands of pharmacy chains. Differentiation now hinges on concentration ratios (1:1 to 1:4 extract), low-sugar positioning for paediatric lines, and Track-and-Trace serialization that meets the 2025 China Drug Traceability mandate. R&D budgets remain modest, yet several Guangxi and Hubei firms share grants under the Western Traditional Medicine Upgrade Programme, accelerating pilot studies on biomarker-standardised extracts and shelf-life extension to twenty-four months without preservatives. Supply-chain risk persists because heavy-metal and pesticide limits tighten each year, forcing smaller producers to outsource testing and eroding cost advantages.

Hubei Yujindan Pharmaceutical Co., Ltd. focuses on premium pricing backed by 1:3 concentrated extract

Guangxi Gehongtang Pharmaceutical Co., Ltd. pursues regional expansion into southwestern Guizhou hospitals

Jianmin Pharmaceutical Group Co., Ltd. leverages vertical integration with 300 ha fritillaria plantation

Jiangxi Chengzhi Yongfeng Pharmaceutical Co., Ltd. emphasises OEM tie-ups with e-commerce pharmacy brands

Hubei Meisichuang Pharmaceutical Co., Ltd. invests in innovation pipeline for alcohol-free paediatric syrup

Sunflower Pharmaceutical Group Hubei Wudang Co., Ltd. drives local manufacturing for 2025 traceability compliance

Key Chuan Bei Qing Fei Tang Jiang Companies20 items

Hubei Yujindan Pharmaceutical Co., Ltd.

Hubei Yanhuang Bencao Pharmaceutical Co., Ltd.

Guangxi Gehongtang Pharmaceutical Co., Ltd.

Jianmin Pharmaceutical Group Co., Ltd.

Jiangxi Chengzhi Yongfeng Pharmaceutical Co., Ltd.

Hubei Meisichuang Pharmaceutical Co., Ltd.

Jiangxi Tonggu Renhe Pharmaceutical Co., Ltd.

Hubei Wushi Pharmaceutical Co., Ltd.

Huiyingbi Group Anhui Pharmaceutical Co., Ltd.

Sunflower Pharmaceutical Group Hubei Wudang Co., Ltd.

Hubei Nordeson Pharmaceutical Co., Ltd.

Wuhan Jianmin Dapeng Pharmaceutical Co., Ltd.

Guangxi Zhengtang Pharmaceutical Co., Ltd.

Guangdong Yihe Pharmaceutical Co., Ltd.

Guangxi Shibiao Pharmaceutical Co., Ltd.

Guangxi Tiantianle Pharmaceutical Co., Ltd.

Guangxi Hercules Pharmaceutical Co., Ltd.

Shanghai Baolong Anqing Pharmaceutical Co., Ltd.

Wuhan Kangle Pharmaceutical Co., Ltd.

Jiangxi Puzheng Pharmaceutical Co., Ltd.

Market Ecosystem

The Chuan Bei Qing Fei Tang Jiang ecosystem stretches from high-altitude Fritillaria cirrhosa collectors to hospital and retail pharmacy counters, with value accruing at each node that transforms raw botanical material into standardised syrup. Upstream actors secure geographically restricted bulbs; midstream processors extract, concentrate and blend active fractions under GMP licences; downstream channels, including hospital tenders and OTC chains, dispense the finished preparation to paediatric and geriatric end users. Technology providers insert themselves in the middle, offering TLC/HPLC fingerprinting systems that authenticate alkaloid content and enable batch-to-batch consistency claims required by China’s NMPA post-2019 TCM quality decree.

Wild bulb gatherers — harvest and dry Fritillaria bulbs under provincial quotas

Licensed extract producers — decoct, filter and vacuum-concentrate crude drug into soft extract

Formulation manufacturers — blend extract with honey, preservatives and excipients to produce syrup

Analytical tech vendors — supply chromatography columns, reference standards and validation protocols

Provential tender platforms — host bulk procurement auctions for public hospitals

Cold-chain logistics firms — maintain 5–15 °C transport to prevent sugar crystallisation and microbial growth

TCM prescribers — determine dosage and duration for cough syndromes coded in ICD-11 TCM

Adoption is controlled by NMPA batch release certificates; without the green tag, finished syrup cannot move past provincial depots. Supply risk centres on Sichuan-Tibet plateau bulb yields, which fall 30–40 % in drought years, pushing extractors to hold 18-month safety stocks. Switching costs are high for manufacturers because altering excipient ratios triggers new bioequivalence dossiers; hence partnerships with analytical tech vendors become sticky once methods are validated. In western provinces, hospital inclusion lists privilege local SOE brands, while eastern cities accept any NMPA-approved product, fragmenting channel strategies.

Recent Industry Insights

Over the past 18 months, the Chuan Bei Qing Fei Tang Jiang industry trends have been reshaped by a surge in herbal traceability partnerships: three leading growers in Sichuan inked blockchain-based agreements with Tianjin-based logistics tech start-ups, enabling QR-code verification of wild-crafted fritillaria bulbs and boosting export premiums by 8%. Meanwhile, Guangyao Group completed the acquisition of a 62 % stake in the century-old Tong Jun Ge syrup facility for USD 87 million, integrating AI-driven extraction lines that cut decoction time by 30 % and securing a dominant position in pediatric formulations. On the regulatory front, the NMPA's 2023 addendum to the Traditional Chinese Medicine Registration Rules now exempts Chuan Bei Qing Fei Tang Jiang from stability re-testing if packaged in nitrogen-flushed pouches—accelerating new SKU launches by roughly four months. A shift toward sugar-free and vegan SKUs has pushed market leaders to introduce monk-fruit-sweetened SKUs, capturing calorie-conscious Gen-Z consumers and driving a 12 % value uptick in first-tier cities.

Analyst Overview

The Chuan Bei Qing Fei Tang Jiang market outlook signals a highly attractive niche within China’s OTC phytotherapy sector, driven by rising respiratory health awareness and aging demographics. Margins remain comfortably above 40 %, yet competitive intensity is sharpening as regional TCM titans and cross-category OTC giants expand SKUs, squeezing shelf space and inflating promotional rebates.

Long-term, we forecast a 6–7 % CAGR through 2029, underpinned by hospital formulary re-listings and e-pharmacy penetration, but volume growth will lag value due to premiumization. Innovation is pivoting to sugar-free syrups, metered-dose sachets, and traceable Chuanbeinoid QR codes—raising entry costs for smaller decoction houses.

Demand currently eclipses certified wild Chuanbei supply by ~25 %, fuelling price volatility and substitution risk. Key risks include ephemeral regulatory easing, climate-linked harvest shocks, and synthetic alkaloid entrants that could erode differentiation within five years.

12 items

1. Executive Summary

2. Chuan Bei Qing Fei Tang Jiang Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Chuan Bei Qing Fei Tang Jiang Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Chuan Bei Qing Fei Tang Jiang Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Chuan Bei Qing Fei Tang Jiang Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Chuan Bei Qing Fei Tang Jiang Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Chuan Bei Qing Fei Tang Jiang Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Chuan Bei Qing Fei Tang Jiang Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Chuan Bei Qing Fei Tang Jiang Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Chuan Bei Qing Fei Tang Jiang Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Chuan Bei Qing Fei Tang Jiang Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Chuan Bei Qing Fei Tang Jiang Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Chuan Bei Qing Fei Tang Jiang Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Chuan Bei Qing Fei Tang Jiang Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Chuan Bei Qing Fei Tang Jiang Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Chuan Bei Qing Fei Tang Jiang Market Competition by Key Manufacturers

9.1. Global Chuan Bei Qing Fei Tang Jiang Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Chuan Bei Qing Fei Tang Jiang: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Hubei Yujindan Pharmaceutical Co., Ltd.

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Hubei Yanhuang Bencao Pharmaceutical Co., Ltd.

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Guangxi Gehongtang Pharmaceutical Co., Ltd.

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Jianmin Pharmaceutical Group Co., Ltd.

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Jiangxi Chengzhi Yongfeng Pharmaceutical Co., Ltd.

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Hubei Meisichuang Pharmaceutical Co., Ltd.

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Jiangxi Tonggu Renhe Pharmaceutical Co., Ltd.

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Hubei Wushi Pharmaceutical Co., Ltd.

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Huiyingbi Group Anhui Pharmaceutical Co., Ltd.

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Sunflower Pharmaceutical Group Hubei Wudang Co., Ltd.

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Hubei Nordeson Pharmaceutical Co., Ltd.

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Wuhan Jianmin Dapeng Pharmaceutical Co., Ltd.

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Guangxi Zhengtang Pharmaceutical Co., Ltd.

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Guangdong Yihe Pharmaceutical Co., Ltd.

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Guangxi Shibiao Pharmaceutical Co., Ltd.

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. Guangxi Tiantianle Pharmaceutical Co., Ltd.

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

10.17. Guangxi Hercules Pharmaceutical Co., Ltd.

10.17.1. Company Basic Information and Sales Area

10.17.2. Main Business/Business Overview

10.17.3. Product Portfolio

10.17.4. Financial

10.17.5. Recent Industry Insights

10.17.6. SWOT Analysis

10.18. Shanghai Baolong Anqing Pharmaceutical Co., Ltd.

10.18.1. Company Basic Information and Sales Area

10.18.2. Main Business/Business Overview

10.18.3. Product Portfolio

10.18.4. Financial

10.18.5. Recent Industry Insights

10.18.6. SWOT Analysis

10.19. Wuhan Kangle Pharmaceutical Co., Ltd.

10.19.1. Company Basic Information and Sales Area

10.19.2. Main Business/Business Overview

10.19.3. Product Portfolio

10.19.4. Financial

10.19.5. Recent Industry Insights

10.19.6. SWOT Analysis

10.20. Jiangxi Puzheng Pharmaceutical Co., Ltd.

10.20.1. Company Basic Information and Sales Area

10.20.2. Main Business/Business Overview

10.20.3. Product Portfolio

10.20.4. Financial

10.20.5. Recent Industry Insights

10.20.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Chuan Bei Qing Fei Tang Jiang Market

Figure 4: Global Chuan Bei Qing Fei Tang Jiang Market: Drivers

Figure 5: Global Chuan Bei Qing Fei Tang Jiang Market: Challenges

Figure 6: Global Chuan Bei Qing Fei Tang Jiang Market: Trends

Figure 7: Global Chuan Bei Qing Fei Tang Jiang Market: Opportunity

Figure 8: Global Chuan Bei Qing Fei Tang Jiang Market: Restraint

Figure 9: Global Chuan Bei Qing Fei Tang Jiang Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Chuan Bei Qing Fei Tang Jiang Market Value (USD Million) By Region

Figure 19: Global Chuan Bei Qing Fei Tang Jiang Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Chuan Bei Qing Fei Tang Jiang Market Value (USD Million) By Region

Figure 27: Global Chuan Bei Qing Fei Tang Jiang Market Share (%) By: Regions (2032)

Figure 28: Global Chuan Bei Qing Fei Tang Jiang Market Volume (K) By Region

Figure 29: Global Chuan Bei Qing Fei Tang Jiang Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Chuan Bei Qing Fei Tang Jiang Market Value (USD Million) By Region

Figure 37: Global Chuan Bei Qing Fei Tang Jiang Market Share (%) By: Regions (2032)

Figure 38: Global Chuan Bei Qing Fei Tang Jiang Market Volume (K) By Region

Figure 39: Global Chuan Bei Qing Fei Tang Jiang Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

135 items

Table 1: Market Segmentation Analysis

Table 2: Global Chuan Bei Qing Fei Tang Jiang Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Chuan Bei Qing Fei Tang Jiang Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Chuan Bei Qing Fei Tang Jiang Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Chuan Bei Qing Fei Tang Jiang Market Value (USD Million) By Region

Table 14: Global Chuan Bei Qing Fei Tang Jiang Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Chuan Bei Qing Fei Tang Jiang Market Volume (K) By Region

Table 31: Global Chuan Bei Qing Fei Tang Jiang Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Chuan Bei Qing Fei Tang Jiang Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Chuan Bei Qing Fei Tang Jiang Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Chuan Bei Qing Fei Tang Jiang Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Hubei Yujindan Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 52: Hubei Yujindan Pharmaceutical Co., Ltd.. Products Portfolio

Table 53: Hubei Yanhuang Bencao Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 54: Hubei Yanhuang Bencao Pharmaceutical Co., Ltd.. Products Portfolio

Table 55: Guangxi Gehongtang Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 56: Guangxi Gehongtang Pharmaceutical Co., Ltd.. Products Portfolio

Table 57: Jianmin Pharmaceutical Group Co., Ltd. Basic Information And Sales Area

Table 58: Jianmin Pharmaceutical Group Co., Ltd.. Products Portfolio

Table 59: Jiangxi Chengzhi Yongfeng Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 60: Jiangxi Chengzhi Yongfeng Pharmaceutical Co., Ltd.. Products Portfolio

Table 61: Hubei Meisichuang Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 62: Hubei Meisichuang Pharmaceutical Co., Ltd.. Products Portfolio

Table 63: Jiangxi Tonggu Renhe Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 64: Jiangxi Tonggu Renhe Pharmaceutical Co., Ltd.. Products Portfolio

Table 65: Hubei Wushi Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 66: Hubei Wushi Pharmaceutical Co., Ltd.. Products Portfolio

Table 67: Huiyingbi Group Anhui Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 68: Huiyingbi Group Anhui Pharmaceutical Co., Ltd.. Products Portfolio

Table 69: Sunflower Pharmaceutical Group Hubei Wudang Co., Ltd. Basic Information And Sales Area

Table 70: Sunflower Pharmaceutical Group Hubei Wudang Co., Ltd.. Products Portfolio

Table 71: Hubei Nordeson Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 72: Hubei Nordeson Pharmaceutical Co., Ltd.. Products Portfolio

Table 73: Wuhan Jianmin Dapeng Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 74: Wuhan Jianmin Dapeng Pharmaceutical Co., Ltd.. Products Portfolio

Table 75: Guangxi Zhengtang Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 76: Guangxi Zhengtang Pharmaceutical Co., Ltd.. Products Portfolio

Table 77: Guangdong Yihe Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 78: Guangdong Yihe Pharmaceutical Co., Ltd.. Products Portfolio

Table 79: Guangxi Shibiao Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 80: Guangxi Shibiao Pharmaceutical Co., Ltd.. Products Portfolio

Table 81: Guangxi Tiantianle Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 82: Guangxi Tiantianle Pharmaceutical Co., Ltd.. Products Portfolio

Table 83: Guangxi Hercules Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 84: Guangxi Hercules Pharmaceutical Co., Ltd.. Products Portfolio

Table 85: Shanghai Baolong Anqing Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 86: Shanghai Baolong Anqing Pharmaceutical Co., Ltd.. Products Portfolio

Table 87: Wuhan Kangle Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 88: Wuhan Kangle Pharmaceutical Co., Ltd.. Products Portfolio

Table 89: Jiangxi Puzheng Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 90: Jiangxi Puzheng Pharmaceutical Co., Ltd.. Products Portfolio

Table 91: Global Market Value (USD Million) (2025-2032) By Type

Table 92: Global Market Share (%) By Type (2032)

Table 93: Global Market Value (USD Million) (2025-2032) By Application

Table 94: Global Market Share (%) By Application (2032)

Table 95: Global Market Volume (K) (2025-2032) By Type

Table 96: Global Market Share (%) By Type (2032)

Table 97: Global Market Volume (K) (2025-2032) By Application

Table 98: Global Market Share (%) By Application (2032)

Table 99: Global Chuan Bei Qing Fei Tang Jiang Market Value (USD Million) By Region

Table 100: Global Chuan Bei Qing Fei Tang Jiang Market Share (%) By Region (2025-2032)

Table 101: North America Market Value (USD Million) (2025-2032) By Country

Table 102: North America Market Value (USD Million) (2025-2032) By Type

Table 103: North America Market Value (USD Million) (2025-2032) By Application

Table 104: Europe Market Value (USD Million) (2025-2032) By Country

Table 105: Europe Market Value (USD Million) (2025-2032) By Type

Table 106: Europe Market Value (USD Million) (2025-2032) By Application

Table 107: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 108: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 109: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 110: South America Market Value (USD Million) (2025-2032) By Country

Table 111: South America Market Value (USD Million) (2025-2032) By Type

Table 112: South America Market Value (USD Million) (2025-2032) By Application

Table 113: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 114: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 115: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 116: Global Chuan Bei Qing Fei Tang Jiang Market Volume (K) By Region

Table 117: Global Chuan Bei Qing Fei Tang Jiang Market Share (%) By Region (2025-2032)

Table 118: North America Market Volume (K) (2025-2032) By Country

Table 119: North America Market Volume (K) (2025-2032) By Type

Table 120: North America Market Volume (K) (2025-2032) By Application

Table 121: Europe Market Volume (K) (2025-2032) By Country

Table 122: Europe Market Volume (K) (2025-2032) By Type

Table 123: Europe Market Volume (K) (2025-2032) By Application

Table 124: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 125: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 126: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 127: South America Market Volume (K) (2025-2032) By Country

Table 128: South America Market Volume (K) (2025-2032) By Type

Table 129: South America Market Volume (K) (2025-2032) By Application

Table 130: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 131: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 132: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 133: Research Programs/Design For This Report

Table 134: Key Data Information From Secondary Sources

Table 135: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Chuan Bei Qing Fei Tang Jiang Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	70.20 million
Revenue forecast in 2033	99.83 million
Growth rate	CAGR of 4.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Hubei Yujindan Pharmaceutical Co., Ltd.; Hubei Yanhuang Bencao Pharmaceutical Co., Ltd.; Guangxi Gehongtang Pharmaceutical Co., Ltd.; Jianmin Pharmaceutical Group Co., Ltd.; Jiangxi Chengzhi Yongfeng Pharmaceutical Co., Ltd.; Hubei Meisichuang Pharmaceutical Co., Ltd.; Jiangxi Tonggu Renhe Pharmaceutical Co., Ltd.; Hubei Wushi Pharmaceutical Co., Ltd.; Huiyingbi Group Anhui Pharmaceutical Co., Ltd.; Sunflower Pharmaceutical Group Hubei Wudang Co., Ltd.; Hubei Nordeson Pharmaceutical Co., Ltd.; Wuhan Jianmin Dapeng Pharmaceutical Co., Ltd.; Guangxi Zhengtang Pharmaceutical Co., Ltd.; Guangdong Yihe Pharmaceutical Co., Ltd.; Guangxi Shibiao Pharmaceutical Co., Ltd.; Guangxi Tiantianle Pharmaceutical Co., Ltd.; Guangxi Hercules Pharmaceutical Co., Ltd.; Shanghai Baolong Anqing Pharmaceutical Co., Ltd.; Wuhan Kangle Pharmaceutical Co., Ltd.; Jiangxi Puzheng Pharmaceutical Co., Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options